Literature DB >> 26663216

Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study.

Douglas H J Elder1, Jagdeep S S Singh1, Daniel Levin1, Louise A Donnelly1, Anna-Maria Choy1, Jacob George1, Allan D Struthers1, Alex S F Doney1, Chim C Lang1.   

Abstract

AIMS: Controversy exists regarding the importance of glycaemic control in patients with type 2 diabetes mellitus (T2DM) and chronic heart failure (CHF) based on conflicting reports using single baseline glycosyated haemoglobin (HbA1c ). Using the time-weighted mean of serial HbA1c measurements has been found to be a better predictor of diabetic complications as it reflects the glycaemic burden for that individual over time. We therefore sought to confirm this in a large cohort of patients with T2DM and incident CHF. METHODS AND
RESULTS: A time-weighted mean HbA1c was calculated using all HbA1c measurements following CHF diagnosis. Patients were grouped into five categories of HbA1c (≤6.0%, 6.1-7.0%, 7.1-8.0%, 8.1-9.0%, and >9.0%). The relationship between time-weighted mean HbA1c and all-cause death after CHF diagnosis was assessed. A total of 1447 patients with T2DM met the study criteria. During a median follow-up of 2.8 years, there were 826 (57.1%) deaths, with a crude death rate of 155 deaths per 1000 person-years [95% confidence interval (CI) 144-166]. A Cox regression model, adjusted for all significant predictors, with the middle HbA1c category (7.1-8.0%) as the reference, showed a U-shaped relationship between HbA1c and outcome [HbA1c <6.0%, hazard ratio (HR) 2.5, 95% CI 1.8-3.4; HbA1c 6.1-7.0%, HR 1.4, 95% 1.1-1.7; HbA1c 8.1-9.0%, HR 1.3, 95% CI 1.0-1.6; and HbA1c >9.0%, HR 1.8, 95% CI 1.4-2.3]. Further analysis revealed a protective effect of insulin sensitizers (i.e. metformin) (HR 0.7, 95% CI 0.61-0.93) but not other drug classes.
CONCLUSIONS: In patients with T2DM and CHF, our study shows a U-shaped relationship between HbA1c and mortality, with the lowest risk in patients with modest glycaemic control (HbA1c 7.1-8.0%) and those treated with insulin sensitizers.
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Entities:  

Keywords:  Diabetes; HbA1c; Heart failure; Metformin; Outcomes

Mesh:

Substances:

Year:  2015        PMID: 26663216     DOI: 10.1002/ejhf.455

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  24 in total

Review 1.  Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes.

Authors:  Aakash Bavishi; Ravi B Patel
Journal:  Heart Fail Clin       Date:  2020-07-21       Impact factor: 3.179

2.  Effects of glycemic control on in-hospital mortality among acute heart failure patients with reduced, mid-range, and preserved ejection fraction.

Authors:  Kenichi Matsushita; Kazumasa Harada; Tetsuro Miyazaki; Takamichi Miyamoto; Kiyoshi Iida; Shuzou Tanimoto; Mayuko Yagawa; Makoto Takei; Yuji Nagatomo; Toru Hosoda; Hideaki Yoshino; Takeshi Yamamoto; Ken Nagao; Morimasa Takayama
Journal:  Heart Vessels       Date:  2018-03-14       Impact factor: 2.037

3.  Heart Failure in Patients with Diabetes Mellitus.

Authors:  Giuseppe Mc Rosano; Cristiana Vitale; Petar Seferovic
Journal:  Card Fail Rev       Date:  2017-04

Review 4.  Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus.

Authors:  Amanda Trang; David Aguilar
Journal:  Curr Heart Fail Rep       Date:  2017-12

Review 5.  Clinical impact of oral antidiabetic medications in heart failure patients.

Authors:  Alberto Palazzuoli; Elena Ceccarelli; Gaetano Ruocco; Ranuccio Nuti
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

6.  Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society.

Authors:  Eiichi Araki; Atsushi Tanaka; Nobuya Inagaki; Hiroshi Ito; Kohjiro Ueki; Toyoaki Murohara; Kenjiro Imai; Masataka Sata; Takehiro Sugiyama; Hideki Ishii; Shunsuke Yamane; Takashi Kadowaki; Issei Komuro; Koichi Node
Journal:  Diabetol Int       Date:  2020-11-30

Review 7.  Common Co-Morbidities in Heart Failure - Diabetes, Functional Mitral Regurgitation and Sleep Apnoea.

Authors:  Andrew J Stewart Coats
Journal:  Int J Heart Fail       Date:  2019-10-15

8.  Contemporary risk estimates of three HbA1c variables in relation to heart failure following diagnosis of type 2 diabetes.

Authors:  Stanko Skrtic; Claudia Cabrera; Marita Olsson; Volker Schnecke; Marcus Lind
Journal:  Heart       Date:  2016-09-19       Impact factor: 5.994

9.  De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study.

Authors:  Luis M Pérez-Belmonte; Michele Ricci; Jaime Sanz-Cánovas; Lidia Cobos-Palacios; María D López-Carmona; M Isabel Ruiz-Moreno; Mercedes Millán-Gómez; M Rosa Bernal-López; Sergio Jansen-Chaparro; Ricardo Gómez-Huelgas
Journal:  J Clin Med       Date:  2021-05-08       Impact factor: 4.241

10.  Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.

Authors:  Jagdeep S S Singh; Amir Fathi; Keeran Vickneson; Ify Mordi; Mohapradeep Mohan; J Graeme Houston; Ewan R Pearson; Allan D Struthers; Chim C Lang
Journal:  Cardiovasc Diabetol       Date:  2016-07-15       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.